# Inhibikase Therapeutics Inc. (IKT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.50, market value $349 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Inhibikase Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.8×**. The shares trade at 2.8× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -12.2%** (5-yr avg -93.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -27.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 518.4%**. Return on all capital, debt included, is 518.4%: comfortably above what that capital costs.
- **Return on assets: -15.2%**. Each dollar of assets produces -15.2% of profit.

## Growth
- **EPS growth (1 yr): 57.8%**. Earnings per share rose 57.8%.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 6.2×**. It would take 6.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 21.70** (quick 21.70). Current assets cover the next year's liabilities 21.70 times.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Inhibikase Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 46.2%** (YTD 22.0%, 3-mo 53.4%). The shares are up 46.2% over twelve months including dividends.
- **From 52-week high: -4.2%** (88.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 1.63** (volatility 64%). Beta of 1.63 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IKT · Page: https://foliofundamentals.com/stocks/ikt

Not investment advice.